ÂÜŔňÂŇÂ×

Dr. Yafit Stark is Vice President at Teva Pharmaceutical Industries. Ltd., Chief Clinical Officer and Head of Oncology Emerging Therapeutic Areas and Biogenerics Innovative R&D. Dr. Stark joined Teva in 1987, From 1991 to 1994, she was based in the US, where she established the Innovative R&D Division of Teva USA and was responsible for the clinical development of Copaxone®. Dr. Stark then established and managed the Innovative R&D Division’s global clinical research and clinical development of all innovative products at Teva.

Dr. Stark holds a Ph.D. degree in Pathology from the Sackler School of Medicine, Tel Aviv University, and a Post-Doctorate in Immuno-Histopathology from Tel Aviv University and the Weizmann Institute of Science. She served as a member of the academic staff of the Sackler School of Medicine and continues to lecture on Pathology and Oncology Drug Development in the School of Medicine’s College for Advanced Degrees. Dr. Stark is a member of the Nominating/Elections Committee of the Association of Clinical Research Professionals and an active member of Tnufa, the Project Funding Evaluation Committee of the Chief Scientist’s Office at the Israeli Ministry of Industry, Trade, and Labor. Dr. Stark has served as a member of Omnix’s Board of Directors since the company’s inception and is the leading advisor for all clinical and regulatory aspects.